Based on 3,800 glioma and GBM patients across four relevant datasets, including CGGA and TCGA for RNA-Seq data, the Ivy Glioblastoma Atlas Project (Ivy-GAP) and TCIA for clinicopathological data, and The Clinical Proteomic Tumor Analysis Consortium Glioblastoma Multiforme (CPTAC-GBM) for proteomic data, radiogenomic analysis revealed that SOCS3 expression level was significantly correlated with radiographical features of perfusion imaging, and it could be a potential biomarker for predicting treatment response of bevacizumab in GBM patients [95]. This evidence concerns the gene SOCS3 and glioblastoma.